Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
UBS
Express Scripts
McKesson
Boehringer Ingelheim
Johnson and Johnson

Generated: September 16, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR CELLCEPT

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Clinical Trials for Cellcept

Trial ID Title Status Sponsor Phase Summary
NCT00023231 Pediatric Kidney Transplant Without Calcineurin Inhibitors Completed National Institute of Allergy and Infectious Diseases (NIAID) N/A The purpose of this study is to see the effect of using drugs other than calcineurin inhibitors to improve the rate of kidney transplant failure. Kidney transplantation can help children with end-stage kidney disease. However, it has been difficult to find treatment for donor graft rejection that does not have a lot of side effects. Researchers hope to find treatments (immunosuppressants) with fewer side effects. One approach is to avoid using calcineurin inhibitors and to try a new drug known as sirolimus instead. Another is to use steroids less often. This study will test whether using sirolimus, fewer steroid treatments, MMF, and certain antibodies will improve long-term graft survival in children receiving kidney transplants from living donors.
NCT00048152 A Study to Assess Use of Zenapax (Daclizumab) and CellCept (Mycophenolate Mofetil) to Improve Kidney Function in Kidney Transplant Patients Completed Hoffmann-La Roche Phase 3 This study will compare kidney function in kidney transplant patients following treatment with various combinations of Zenapax, CellCept, corticosteroids, and Neoral (Cyclosporine). The anticipated time on study treatment is 6-12 months, and the target sample size is 500+ individuals.
NCT00048165 A Study to Evaluate the Efficacy and Safety of Zenapax in Combination With CellCept, Cyclosporine, and Corticosteroids in Patients Undergoing Cardiac Transplantation Completed Hoffmann-La Roche Phase 4 The purpose of the study is to compare the number of randomized participants in each treatment group who experience an acute rejection episode in the first 6 months after undergoing cardiac transplantation.
NCT00087581 Study of Therapeutic Monitoring of Mycophenolate Mofetil (MMF/CellCept) After Kidney Transplantation Completed Hoffmann-La Roche Phase 4 This three-arm study will evaluate the efficacy and safety of various dosing regimens of MMF combined with various dosing regimens of calcineurin inhibitor (CNI), either cyclosporine or tacrolimus, in participants who have undergone kidney transplantation. Participants will be randomized to one of three dosing regimens to receive concentration-controlled MMF with reduced CNI, concentration-controlled MMF with standard CNI, or fixed-dose MMF with standard CNI. Participants will be followed for 20-24 months after randomization.
>Trial ID >Title >Status >Phase >Summary

Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Cellcept

Condition Name

Condition Name for Cellcept
Intervention Trials
Kidney Transplantation 28
Lymphoma 8
Leukemia 8
Acute Myeloid Leukemia 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Cellcept
Intervention Trials
Leukemia 15
Preleukemia 12
Myelodysplastic Syndromes 12
Leukemia, Myeloid, Acute 11
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Cellcept

Trials by Country

Trials by Country for Cellcept
Location Trials
United States 381
Canada 46
Germany 21
Japan 16
Spain 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Cellcept
Location Trials
California 30
New York 26
Texas 25
Pennsylvania 25
Ohio 19
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Cellcept

Clinical Trial Phase

Clinical Trial Phase for Cellcept
Clinical Trial Phase Trials
Phase 4 51
Phase 3 29
Phase 2/Phase 3 3
[disabled in preview] 36
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Cellcept
Clinical Trial Phase Trials
Completed 91
Terminated 25
Recruiting 23
[disabled in preview] 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Cellcept

Sponsor Name

Sponsor Name for Cellcept
Sponsor Trials
Hoffmann-La Roche 38
M.D. Anderson Cancer Center 8
Novartis 7
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Cellcept
Sponsor Trials
Other 134
Industry 114
NIH 17
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Mallinckrodt
UBS
QuintilesIMS
AstraZeneca
Chubb
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.